Top

Published in:

Open Access 01-12-2018 | Research article

Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients

Authors: Erwin Krikken, Vitaliy Khlebnikov, Moritz Zaiss, Rajni A. Jibodh, Paul J. van Diest, Peter R. Luijten, Dennis W. J. Klomp, Hanneke W. M. van Laarhoven, Jannie P. Wijnen

Published in: Breast Cancer Research | Issue 1/2018

Abstract

Background

The purpose of this work was to investigate noninvasive early detection of treatment response of breast cancer patients to neoadjuvant chemotherapy (NAC) using chemical exchange saturation transfer (CEST) measurements sensitive to amide proton transfer (APT) at 7 T.

Methods

CEST images were acquired in 10 tumors of nine breast cancer patients treated with NAC. APT signals in the tumor, before and after the first cycle of NAC, were quantified using a three-pool Lorentzian fit of the z-spectra in the region of interest. The changes in APT were subsequently related to pathological response after surgery defined by the Miller-Payne system.

Results

Significant differences (P < 0.05, unpaired Mann-Whitney test) were found in the APT signal before and after the first cycle of NAC in six out of 10 lesions, of which two showed a pathological complete response. Of the remaining four lesions, one showed a pathological complete response. No significant difference in changes of APT signal were found between the different pathological responses to NAC treatment (P > 0.05, Kruskal-Wallis test).

Conclusions

This preliminary study shows the feasibility of using APT CEST magnetic resonance imaging as a noninvasive biomarker to assess the effect of NAC in an early stage of NAC treatment of breast cancer patients.

Trial registration

Registration number, NL49333.041.14/NTR4980. Registered on 16 October 2014.

Loibl S, Von Minckwitz G, Blohmer J, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13(11):1434–42.CrossRefPubMed

Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24(12):1940–9.CrossRefPubMed

Kaufmann M, Von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18(11):1927–34.CrossRefPubMed

Kaufmann M, Von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2011;19:1508–16.CrossRefPubMed

Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–93.CrossRefPubMed

Bonadonna G, Valagussa P, Zucali R, Salvadori B. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin. 1995;45(4):227–43.CrossRefPubMed

Tudorica A, Oh KY, Chui SYC, et al. Early prediction and evaluation of breast cancer response to neoadjuvant chemotherapy using quantitative DCE-MRI. Transl Oncol. 2016;9(1):8–17.CrossRefPubMedPubMedCentral

Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol. 2010;11(1):92–102.CrossRefPubMed

Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology. 2010;256(2):348–64.CrossRefPubMed

10.

Wolff SD, Balaban RS. NMR imaging of labile proton exchange. J Magn Reson. 1990;86(1):164–9.

11.

Van Zijl PCM, Zhou J, Mori N, Payen JF, Wilson D, Mori S. Mechanism of magnetization transfer during on-resonance water saturation. A new approach to detect mobile proteins, peptides, and lipids. Magn Reson Med. 2003;49(3):440–9.CrossRefPubMed

12.

Zhou JY, Lal B, Wilson DA, Laterra J, van Zijl PCM. Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med. 2003;50(6):1120–6.CrossRefPubMed

13.

Dula AN, Arlinghaus LR, Dortch RD, et al. Amide proton transfer imaging of the breast at 3 T: establishing reproducibility and possible feasibility assessing chemotherapy response. Magn Reson Med. 2013;70:216–24.CrossRefPubMed

14.

Klomp DWJ, Dula AN, Arlinghaus LR, et al. Amide proton transfer imaging of the human breast at 7T: development and reproducibility. NMR Biomed. 2013;26(10):1271–7.CrossRefPubMedPubMedCentral

15.

Zaiss M, Windschuh J, Paech D, et al. Relaxation-compensated CEST-MRI of the human brain at 7T: unbiased insight into NOE and amide signal changes in human glioblastoma. Neuroimage. 2015;112:180–8.CrossRefPubMed

16.

Zaiss M, Xu J, Goerke S, et al. Inverse Z-spectrum analysis for spillover-, MT-, and T1-corrected steady-state pulsed CEST-MRI—application to pH-weighted MRI of acute stroke. NMR Biomed. 2014;27(3):240–52.CrossRefPubMedPubMedCentral

17.

Khlebnikov V, Polders D, Hendrikse J, et al. Amide proton transfer (APT) imaging of brain tumors at 7 T : the role of tissue water T1-relaxation properties. Magn Reson Imaging. 2017;77:1525–32.

18.

Khlebnikov V, Siero JCW, Wijnen J, et al. Is there any difference in amide and NOE CEST effects between white and gray matter at 7 T? J Magn Reson. 2016;272:82–6.CrossRefPubMed

19.

Dula AN, Dewey BE, Arlinghaus LR, et al. Optimization of 7-T chemical exchange saturation transfer parameters for validation of glycosaminoglycan and amide proton transfer of fibroglandular breast tissue. Radiology. 2014;275(1):255–61.CrossRefPubMedPubMedCentral

20.

Van Der Velden TA, Italiaander M, Der Kemp WJM V, et al. Radiofrequency configuration to facilitate bilateral breast 31P MR spectroscopic imaging and high-resolution MRI at 7 Tesla. Magn Reson Med. 2015;74(6):1803–10.CrossRefPubMed

21.

Klomp DWJ, van der Kemp WJM, Korteweg M, Wijnen JP, Van De Bosch M, Luijten PR. P MRS at 7T can be more sensitive and specific than 1 H MRS in monitoring breast cancer treatment. Proc Intl Soc Mag Reson Med. 2011;19:343.

22.

Hancu I, Govenkar A, Lenkinski RE, Lee SK. On shimming approaches in 3T breast MRI. Magn Reson Med. 2013;69(3):862–7.CrossRefPubMed

23.

Khlebnikov V, Geades N, Klomp DWJ, Hoogduin H, Gowland P, Mougin O. Comparison of pulsed three-dimensional CEST acquisition schemes at 7 Tesla: steady state versus pseudosteady state. Magn Reson Med. 2017;77:2280–7.CrossRefPubMed

24.

Kim M, Gillen J, Landman BA, Zhou J, Van Zijl PCM. Water saturation shift referencing (WASSR) for chemical exchange saturation transfer (CEST) experiments. Magn Reson Med. 2009;61(6):1441–50.CrossRefPubMedPubMedCentral

25.

Windschuh J, Zaiss M, Meissner J, et al. Correction of B1-inhomogeneities for relaxation-compensated CEST imaging at 7T. NMR Biomed. 2015;28:529–37.CrossRefPubMed

26.

Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320–7.CrossRefPubMed

27.

Salhotra A, Lal B, Laterra J, Sun PZ, van Zijl PCM, Zhou J. Amide proton transfer imaging of 9L gliosarcoma and human glioblastoma xenografts. NMR Biomed. 2008;21:489–97.CrossRefPubMedPubMedCentral

28.

Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4(5):349–60.CrossRefPubMed

29.

Zhou J, Blakeley JO, Hua J, et al. Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med. 2008;60(4):842–9.CrossRefPubMedPubMedCentral

30.

Zhou J, Tryggestad E, Wen Z, et al. Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med Nature. 2011;17(1):130–4.CrossRef

31.

Jones CK, Schlosser MJ, Van Zijl PCM, Pomper MG, Golay X, Zhou J. Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med. 2006;56(3):585–92.CrossRefPubMed

32.

Wen Z, Hu S, Huang F, et al. Neuroimage MR imaging of high-grade brain tumors using endogenous protein and peptide-based contrast. Neuroimage. 2010;51(2):616–22.CrossRefPubMedPubMedCentral

33.

Zhou J, Payen JF, Wilson DA, Traystman RJ, Van Zijl PCM. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med. 2003;9(8):1085–90.CrossRefPubMed

34.

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.CrossRefPubMed

35.

Yu T, Di G. Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. Chinese J Cancer Res. 2017;29(3):237–52.CrossRef

36.

Delille J, Slanetz PJ, Yeh ED, Kopans DB, Garrido L. Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the T1 relaxation time of breast tissue. Breast J. 2005;11(4):236–41.CrossRefPubMed

37.

Zhang S, Keupp J, Wang X, et al. Z-spectrum appearance and interpretation in the presence of fat: influence of acquisition parameters. Magn Reson Med. 2017;0:1–7.

38.

Zu Z, Li K, Janve VA, Does MD, Gochberg DF. Optimizing pulsed-chemical exchange saturation transfer imaging sequences. Magn Reson Med. 2011;66(4):1100–8.CrossRefPubMedPubMedCentral

39.

Singh A, Cai K, Haris M, Hariharan H. On B1 inhomogeneity correction of in vivo human brain glutamate chemical exchange saturation transfer contrast at 7T. Magn Reson Imaging. 2013;69:818–24.

40.

Khlebnikov V, Windschuh J, Siero JCW, et al. On the transmit field inhomogeneity correction of relaxation-compensated amide and NOE CEST effects at 7 T. NMR Biomed. 2017;30:e3687.CrossRefPubMedCentral

41.

Raaijmakers AJE, Italiaander M, Voogt IJ, et al. The fractionated dipole antenna: a new antenna for body imaging at 7 Tesla. Magn Reson Med. 2016;75(3):1366–74.CrossRefPubMed

42.

Rubovszky G, Horváth Z. Breast cancer: recent advances in the neoadjuvant treatment of breast cancer. J Breast Cancer. 2017;20(2):119–31.CrossRefPubMedPubMedCentral

Title: Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients
Authors: Erwin Krikken
Vitaliy Khlebnikov
Moritz Zaiss
Rajni A. Jibodh
Paul J. van Diest
Peter R. Luijten
Dennis W. J. Klomp
Hanneke W. M. van Laarhoven
Jannie P. Wijnen
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 1/2018
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-018-0982-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2018

Immune characterization of breast cancer metastases: prognostic implications

Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer

Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model

Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters

Breast fibroadenomas are not associated with increased breast cancer risk in an African American contemporary cohort of women with benign breast disease

No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer